Catalyst Capital Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Catalyst Capital Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-3,000	Closed	-$110K	–	469
2014 Q2	$110K	Hold	3,000	–	–	0.02%	320
2014 Q1	$137K	Hold	3,000	–	–	0.03%	269
2013 Q4	$117K	Hold	3,000	–	–	0.04%	232
2013 Q3	$136K	Buy	3,000 +1,500	+100%	+$77K	0.07%	237
2013 Q2	$74K	Buy	+1,500	New	+$79.6K	0.06%	240

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Catalyst Capital Advisors's PLX Position: Q3 2014 in Review

Catalyst Capital Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2014, closing a stake of 3,000 shares — an estimated $110K sold.

Catalyst Capital Advisors first reported a position in PLX in Q2 2013 and held it in 5 quarters. The position peaked at $137K in Q1 2014. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

Catalyst Capital Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2014 after selling out during the quarter.
Catalyst Capital Advisors sold 3,000 Protalix BioTherapeutics shares in Q3 2014, an estimated $110K.
Catalyst Capital Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 5 quarters.
Catalyst Capital Advisors's Protalix BioTherapeutics position peaked at $137K in Q1 2014.
43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on Catalyst Capital Advisors's 13F filing for Q3 2014, filed 13 Nov 2014.